The growing incidence of diabetes, driven by sedentary lifestyles and poor dietary habits, has heightened the need for insulin therapy to effectively control blood glucose levels. Additionally, increased awareness and diagnosis of diabetes worldwide have motivated more individuals to pursue treatment, which in turn is expected to propel the market growth for short-acting insulin products during the forecast period from 2024 to 2030.
LAS VEGAS, Sept. 5, 2024 /PRNewswire/ — DelveInsight’s Short-Acting Insulin Market Insights report provides the current and forecast market analysis, individual leading short-acting insulin companies’ market shares, challenges, short-acting insulin market drivers, barriers, trends, and key market short-acting insulin companies in the market.
Key Takeaways from the Short-Acting Insulin Market Report
- As per DelveInsight estimates, North America is anticipated to dominate the global short-acting insulin market during the forecast period.
- In the drug segment of the short-acting insulin market, the Humulin R category had a significant revenue share in the short-acting insulin market in 2023.
- Notable short-acting insulin companies such as Eli Lilly and Company, Novo Nordisk A/S, Sanofi, Biocon, Torrent Pharmaceuticals Ltd., Gland Pharma, Lupin, Sensile, Zydus Cadila, Cipla, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Pfizer, GlaxoSmithKline, Sun Pharmaceutical Industries, Gan & Lee Pharmaceuticals, ADOCIA SAS, Geropharm LLC, Wockhadt Ltd., Mannkind Corporation, and several others, are currently operating in the short-acting insulin market.
- In March 2024, Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended marketing authorization for Awiqli® (once-weekly basal insulin icodec) for the treatment of diabetes in adults.
- In March 2023, Sanofi reduced the U.S. list price of Lantus®, its most-prescribed insulin, by 78% and capped the out-of-pocket cost of Lantus® at $35 for all patients with commercial insurance.
To read more about the latest highlights related to the short-acting insulin market, get a snapshot of the key highlights entailed in the Global Short-Acting Insulin Market Report
Short-Acting Insulin Overview
Short-acting insulin is designed to manage blood glucose levels by mimicking the body’s natural insulin response. This type of insulin begins to work within 30 minutes after injection, peaks around 2 to 3 hours, and continues to be effective for about 4 to 6 hours. It is often used to control blood sugar spikes that occur during or after meals, making it an essential component of diabetes management.
Due to its rapid onset and relatively short duration, short-acting insulin is ideal for providing flexibility in diabetes care, allowing adjustments based on meal size and timing. This type of insulin is typically administered via subcutaneous injection, and its effectiveness can be influenced by factors such as the site of injection and individual patient metabolism. Proper dosing and timing are crucial to prevent both hyperglycemia and hypoglycemia, emphasizing the need for close monitoring and personalized treatment plans.
Short-Acting Insulin Market Insights
In 2023, North America held the largest share of the short-acting insulin market among all regions. The market in this region is experiencing robust growth due to several key factors. A major driver is the significant rise in the diabetic population, influenced by an aging demographic, increasing obesity rates, and more sedentary lifestyles, all contributing to higher diabetes prevalence. Additionally, there is a growing focus on diabetes awareness and educational programs across North America, which aim to inform the public about the risks, early diagnosis, and proper management of diabetes, thereby boosting the demand for short-acting insulin.
Government initiatives that promote diabetes awareness and early diagnosis can lead to a higher number of diagnoses, particularly of type 1 diabetes that requires insulin therapy. For example, in November 2023, PAHO and WHO organized a hybrid event in Mexico City for World Diabetes Day 2023, which was streamed via Zoom. This event showcased regional achievements, challenges, and opportunities in diabetes prevention and control. Such awareness campaigns can significantly enhance the short-acting insulin market by increasing public awareness, supporting policy development, improving access, facilitating information exchange, engaging stakeholders, addressing regional needs, and strengthening the capacity of healthcare professionals.
The factors mentioned above contribute to the growth of the short-acting insulin market in the region throughout the forecast period.
To know more about why North America is leading the market growth in the short-acting insulin market, get a snapshot of the Short-Acting Insulin Market Outlook
Short-Acting Insulin Market Dynamics
The short-acting insulin market is characterized by dynamic shifts driven by various factors, including technological advancements, increasing prevalence of diabetes, and evolving healthcare policies. As the global incidence of diabetes continues to rise, the demand for effective short-acting insulin products is experiencing significant growth. These insulins are crucial for managing blood glucose levels in diabetic patients, offering rapid onset and relatively short duration of action, which aids in controlling postprandial blood sugar spikes.
Technological advancements play a pivotal role in shaping the short-acting insulin market. The development of insulin analogs and improved delivery mechanisms, such as insulin pumps and pens, has enhanced the efficacy and convenience of insulin therapy. This has led to an increase in patient adherence and satisfaction, further driving market growth. Additionally, innovations in insulin formulations and delivery systems are anticipated to expand the range of options available to patients, catering to diverse needs and preferences.
The competitive landscape of the short-acting insulin market is marked by the presence of major pharmaceutical companies and a continuous stream of new entrants. Established players, such as Novo Nordisk, Sanofi, and Eli Lilly, dominate the market with their well-established products and strong distribution networks. However, the market also sees increased activity from generic manufacturers and biosimilars, which are contributing to price competition and greater accessibility for patients. The introduction of biosimilars, in particular, is expected to influence pricing dynamics and market share distribution.
Regulatory factors and healthcare policies also significantly impact the short-acting insulin market. Governments and health organizations are increasingly focusing on cost control measures and diabetes management guidelines, which can affect insulin pricing and reimbursement policies. For instance, changes in reimbursement rates or new regulations regarding insulin approvals can influence market dynamics and shape competitive strategies for both established and emerging companies.
Overall, the short-acting insulin market is poised for continued growth, driven by rising diabetes prevalence, technological advancements, and evolving market dynamics. As the landscape evolves, stakeholders will need to navigate a complex environment of innovation, competition, and regulatory changes to effectively meet the needs of patients and healthcare systems.
Get a sneak peek at the short-acting insulin market dynamics @ Short-Acting Insulin Market Dynamics Analysis
|
Report Metrics |
Details |
|
Coverage |
Global |
|
Study Period |
2021–2030 |
|
Short-Acting Insulin Market CAGR |
~4% |
|
Short-Acting Insulin Market Size by 2030 |
~USD 9 Billion |
|
Key Short-Acting Insulin Companies |
Eli Lilly and Company, Novo Nordisk A/S, Sanofi, Biocon, Torrent Pharmaceuticals Ltd., Gland Pharma, Lupin, Sensile, Zydus Cadila, Cipla, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Pfizer, GlaxoSmithKline, Sun Pharmaceutical Industries, Gan & Lee Pharmaceuticals, ADOCIA SAS, Geropharm LLC, Wockhadt Ltd., Mannkind Corporation, among others |
Short-Acting Insulin Market Assessment
- Short-Acting Insulin Market Segmentation
- Short-Acting Insulin Market Segmentation By Drug: Lispro (Humalog), Aspart (NovoLog/NovoRapid), Glulisine (Apidra), Humulin R, Novolin R, Actrapid, and Others
- Short-Acting Insulin Market Segmentation By Distribution Channel: Hospital Pharmacies, Drug Store & Retail Pharmacies, and Online Providers
- Short-Acting Insulin Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
Which MedTech key players in the short-acting insulin market are set to emerge as the trendsetter explore @ Short-Acting Insulin Companies
Table of Contents
|
1 |
Short-Acting Insulin Market Report Introduction |
|
2 |
Short-Acting Insulin Market Executive Summary |
|
3 |
Competitive Landscape |
|
4 |
Regulatory Analysis |
|
5 |
Short-Acting Insulin Market Key Factors Analysis |
|
6 |
Short-Acting Insulin Market Porter’s Five Forces Analysis |
|
7 |
Short-Acting Insulin Market Layout |
|
8 |
Short-Acting Insulin Market Company and Product Profiles |
|
9 |
KOL Views |
|
10 |
Project Approach |
|
11 |
About DelveInsight |
|
12 |
Disclaimer & Contact Us |
Interested in knowing the short-acting insulin market by 2030? Click to get a snapshot of the Short-Acting Insulin Market Trends
Related Reports
Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including Enthera, Nano Precision Medical, Oramed, Dompe Farmaceutici, Carmot Therapeutics, Scohia Pharma, Genexine, REMD Biotherapeutics, among others.
Diabetes Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetes companies, including Daewoong Pharmaceutical, Janssen Biotech, Zealand Pharma, BioRestorative Therapies, Elevian, Oramed Pharmaceuticals, ImCyse, Novo Nordisk, Enthera, Precigen, Inc., Japan Tobacco, Avotres, AstraZeneca, Landos Biopharma, Vertex Pharmaceuticals, REMD Biotherapeutics, Inc., Eledon Pharmaceuticals, Eli Lilly and Company, Novo Nordisk A/S, Diamyd Medical, NextCell Pharma, ViaCyte, Op-T LLC, Dompé Farmaceutici S.p.A, ILTOO Pharma, Throne Biotechnologies, Oramed Pharmaceuticals, Janssen Research & Development, LLC, Jaguar Gene Therapy, SQZ Biotechnologies, Genprex, Inc., CRISPR Therapeutics, Biora Therapeutics, Genprex, Inc., among others.
Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 2 diabetes companies, including Sanofi, Eli Lilly and Company, AstraZeneca, Novartis, among others.
Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 1 diabetes companies, including Histogen, Novo Nordisk, Prevention Bio, among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us
Shruti Thakur
[email protected]
+14699457679
https://www.delveinsight.com/medical-devices
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP
